Sunday 18 October 2026 Export OTLK’s income statement to Excel — free account

Outlook Therapeutics, Inc.

In the quarter to June 2026, revenue fell 99.4%, EPS grew 72.7%, free cash flow fell 76.5% and total debt fell 47.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.49 0.01 −2.00%

Follow OTLK

Alert me

Market cap: $121.7M
P/E: 0.0×
Fwd P/E: −1.5×
Dividend yield: —
F-score: n/a
Altman Z: −58.86
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 7.87

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	5	1	1	3	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 121.72

Revenue (1.16)

Net Income (61.12)

Free Cash Flow (56.15)

Net Debt 6.98

Current Ratio 0.81

Debt/Equity (1.75)

P/E ratio 0.00

Fwd P/E (1.47)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 73.18%

Next Y EPS Growth 63.02%

Next Y revenue growth (51.70%)

Next 5Y EPS Growth 56.24%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	23	15	8	11
Receivables	—	—	1	2
Inventory	—	—	3	5
Other	—	—	—	—
	31	27	17	23

	2023	2024	2025	Q'26
Payables	7	8	10	7
ST’ Debt	36	29	30	18
Other	—	—	—	—
	47	43	46	29

Compound Annual Growth %

	10y	5y	3y
Sales	—	(22.99%)	(28.15%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Dec	Mar	Jun	Sep	Year
’26	—	0	0	—	—
’25	—	—	2	0	1
’19	1	1	1	6	8
’18	1	1	1	1	3
’17	0	0	0	3	4

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(15)	(8)	(21)	—	—
’25	(11)	(17)	(12)	(12)	(52)
’24	(13)	(19)	(20)	(17)	(69)
’23	(9)	(8)	(13)	(13)	(43)
’22	(11)	(14)	(21)	(10)	(57)
’21	(13)	(12)	(20)	(9)	(54)
’20	(7)	(7)	(6)	(12)	(32)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Dec	Mar	Jun	Sep	Year
’26	(15)	(8)	(21)	—	—
’25	(11)	(17)	(12)	(12)	(52)
’24	(13)	(19)	(20)	(17)	(69)
’23	(9)	(8)	(13)	(13)	(43)
’22	(11)	(14)	(21)	(10)	(57)
’21	(13)	(12)	(20)	(9)	(54)
’20	(7)	(7)	(6)	(12)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Dec	Mar	Jun	Sep	Year
’26	(0.38)	(0.05)	(0.15)	—	—
’25	0.72	(1.50)	(0.55)	(0.46)	(1.79)
’24	(0.80)	(8.01)	1.74	0.76	(4.06)
’23	(1.60)	(0.60)	(1.60)	(1.00)	(4.80)
’22	(1.60)	(1.80)	(1.60)	(1.30)	(6.23)
’21	(2.40)	(1.80)	(1.40)	(1.60)	(7.00)
’20	(12.40)	(7.20)	(0.60)	4.44	(13.40)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	288.64	125.12	32.80	10.40	9.98	18.58	13.68	4.00	0.87	0.79	Analyst estimates 2026–2028 Powerpack
	High	878.40	632.00	208.00	219.20	34.60	85.20	42.40	40.60	12.85	3.39
People
People	Employees	83	48	56	14	8	9	17	24	23	17
	Revenue/emp, $m	0.04	0.08	0.06	0.58	0.00	0.00	0.00	0.00	0.00	0.08
Income, $m
Income, $m	Revenue	3	4	3	8	—	—	—	—	—	1
	Gross margin, %	100.00	100.00	100.00	100.00	0.00	0.00	0.00	0.00	—	4.05
	EBT	(53)	(38)	(34)	(38)	(39)	(53)	(66)	(59)	(75)	(64)
	EBT margin, %	(1,785.44)	(1,006.10)	(1,092.76)	(465.68)	0.00	0.00	0.00	0.00	0.00	(4,526.12)
	Net income	(53)	(39)	(30)	(35)	(35)	(53)	(66)	(59)	(75)	(62)
	Depreciation	2	3	3	3	1	0	0	0	0	0
Per share, $
Per share, $	Revenue	27.69	25.39	12.52	8.96	0.00	0.00	0.00	0.00	0.00	0.04
	Earnings	(587.20)	(257.94)	(195.20)	(39.60)	(13.40)	(7.00)	(5.87)	(4.80)	(4.06)	(1.79)
	Cash flow	(422.70)	(103.30)	(133.98)	(35.50)	(8.76)	(7.11)	(5.34)	(3.44)	(3.71)	(1.49)
	Capex	(10.21)	(1.95)	(11.28)	(0.48)	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(432.91)	(105.24)	(145.26)	(35.98)	(8.76)	(7.11)	(5.34)	(3.44)	(3.71)	(1.49)
	Book value	(48.08)	(204.71)	(84.39)	(11.84)	0.78	0.60	0.82	(1.15)	(3.94)	(0.92)
	Shares, m	0	0	0	1	4	8	11	13	19	35
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00
	P/S	24.56	8.76	12.52	3.33	—	—	—	—	—	4.70
	P/B	0.00	0.00	0.00	0.00	—	—	—	—	—	0.00
	EV/Sales	24.82	11.46	17.41	3.71	—	—	—	—	—	10.09
	EV/FCF	(1.59)	(2.76)	(1.50)	(0.92)	—	—	—	—	—	(1.51)
Cash, $m
Cash, $m	Operating cash flow	(45)	(16)	(33)	(32)	(32)	(54)	(57)	(43)	(69)	(52)
	Capex	(1)	0	(3)	0	—	—	—	—	—	—
	Free cash flow	(47)	(16)	(36)	(33)	(32)	(54)	(57)	(43)	(69)	(52)
Balance, $m
Balance, $m	Working capital	(15)	(25)	(29)	(7)	2	15	8	(16)	(15)	(28)
	Total debt	3	13	17	11	1	12	11	36	29	30
	Net debt	1	10	15	3	(12)	(3)	(6)	12	15	22
	Shareholders’ equity	(5)	(31)	(21)	(11)	3	5	9	(14)	(73)	(32)
Returns, %
Returns, %	ROA	(209.02)	(173.50)	(223.25)	(182.86)	(265.13)	(249.92)	(257.32)	(193.93)	(246.60)	(263.36)
	ROIC	0.00	0.00	0.00	0.00	0.00	(1,669.72)	(1,744.91)	0.00	0.00	0.00
	ROE	210.30	206.19	162.24	172.96	734.77	(1,430.32)	(989.99)	2,069.13	172.24	118.61

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VYGR Voyager Therapeutics, Inc.	$126.9M	— (loss-making)	— (loss-making)	−39.13% (below 0%: shrinking)	n/m	+24.80% (above 0%: growing)	100.00%	(833.87%)	Compare
HUMA Humacyte, Inc.	$122.1M	— (loss-making)	— (loss-making)	+34.88% (above 0%: growing)	n/m	+17.85% (above 0%: growing)	(203.20%)	(6,649.26%)	Compare
OTLK Outlook Therapeutics, Inc.	$121.7M	— (loss-making)	— (loss-making)	−99.42% (below 0%: shrinking)	n/m	−76.54% (below 0%: shrinking)	(95.40%)	(124,255.17%)
ABOS Acumen Pharmaceuticals, Inc.	$120.8M	— (loss-making)	—	—	n/m	+43.23% (above 0%: growing)	0.00%	0.00%	Compare
SPRB Spruce Biosciences, Inc.	$119.2M	— (loss-making)	— (loss-making)	−75.86% (below 0%: shrinking)	n/m	−152.10% (below 0%: shrinking)	100.00%	0.00%	Compare
NRXP NRx Pharmaceuticals, Inc.	$117.3M	— (loss-making)	— (loss-making)	—	n/m	−142.60% (below 0%: shrinking)	38.69%	(590.83%)	Compare
HURA TuHURA Biosciences, Inc.	$116.6M	— (loss-making)	—	—	n/m	−70.46% (below 0%: shrinking)	0.00%	0.00%	Compare
NERV Minerva Neurosciences, Inc	$115.6M	— (loss-making)	— (loss-making)	—	n/m	−553.48% (below 0%: shrinking)	0.00%	0.00%	Compare
ARMP Armata Pharmaceuticals, Inc.	$114.9M	— (loss-making)	— (loss-making)	+15.72% (above 0%: growing)	n/m	−17.98% (below 0%: shrinking)	100.00%	(410.84%)	Compare
Median of peers	$118.3M	—	—	−11.70%	—	−44.22%	19.35%	(205.42%)

All 614 Biotechnology stocks →